Mark T. Osterman, MD, MSCE

faculty photo
Associate Professor of Medicine at the Hospital of the University of Pennsylvania and the Presbyterian Medical Center of Philadelphia
Department: Medicine

Contact information
Penn Presbyterian Medical Center
Division of Gastroenterology
218 Wright-Saunders Building
51 North 39th Street
Philadelphia, PA 19104
Office: 215-662-8900
Fax: 215-662-0950
Education:
BA (Chemistry)
Harvard University, 1995.
MD (Medicine)
Harvard Medical School, 1999.
MSCE (Clinical Epidemiology)
University of Pennsylvania, 2005.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Selected Publications

Papamichael K, Vajravelu R, Cheifetz AS, Osterman MT: Long-term outcome of infliximab optimization for overcoming immunogenicity in patients with inflammatory bowel disease. Digestive Diseases and Sciences 2018 Notes: In press.

Lewis JD, Scott F, Brensinger CM, Roy JA, Osterman MT, Mamtani R, Chen L, Yun Huifeng, Xie F, Curtis JR: Reduced mortality rates with anti-tumor necrosis factor alpha directed therapy when compared to prolonged corticosteroid therapy for inflammatory bowel disease. Gastroenterology 2017 Notes: Oral presentation at annual Digestive Diseases Week meeting May 2017.

Osterman MT, Lichtenstein GR: Infliximab vs. Adalimumab for UC: Is There a Difference? Clinical Gastroenterology and Hepatology 15: 1197-9, 2017.

Osterman MT, Foley C, Matthias I: Clozapine-induced acute gastrointestinal necrosis: a case report. Journal of Medical Case Reports 11: 270, 2017.

Osterman MT: Ready or not, here they are: Anti-TNF biosimilars for IBD. AGA Perspectives 13: 12-3, 2017.

Vajravelu R, Osterman MT, Aberra FN, Roy JA, Lichtenstein GR, Mamtani R, Goldberg DS, Lewis JD, Scott FI: Indeterminate quantiFERON-TB gold increases likelihood of inflammatory bowel disease treatment delay and hospitalization. Inflammatory Bowel Diseases 24: 217-26, 2017.

Lewis JD, Bewtra M, Scott FI, Brensinger CM, Reed SD, Roy JA, Osterman MT, Mamtani R, Chen L, Yun H, Xie F, Gilroy E, Sandler RS, Chen W, Curtis JR, Johnson R: Patient valued comparative effectiveness of tumor necrosis factor alpha inhibitors and corticosteroids for inflammatory bowel disease. www.pcori.org 2017 Notes: In press.

Osterman MT, Lichtenstein GR: Infliximab vs. Adalimumab for UC: Is There a Difference? Clinical Gastroenterology and Hepatology 2017 Notes: In press.

Papamichael K, Chachu KA, Vajravelu R, Vaughn BP, Ni J, Cheifetz AS, Osterman MT: Improved long-term outcomes of patients with inflammatory bowel disease receiving proactive compared to reactive monitoring of serum concentrations of infliximab. Clinical Gastroenterology and Hepatology 15: 1580-8, 2017.

Cross RK, Osterman MT, Panaccione R, Afzali A, Song X, Shi N, Ding Y, Wang A: The Incidence of Cardiovascular Events in Patients with Crohn's Disease Treated with Vedolizumab and Anti-TNF Therapies. Gastroenterology 2017 Notes: Poster presentation for annual Digestive Diseases Week meeting, Chicago IL, May 2017.

back to top
Last updated: 01/05/2018
The Trustees of the University of Pennsylvania